Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes

• Published in: Diabetes research and clinical practice 2004-11, Vol.66 (2), p.193-201
• Main Authors: Rašlová, K., Bogoev, M., Raz, I., Leth, G., Gall, M-A., Hâncu, N.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Blood Glucose - analysis; Body Weight - drug effects; Circadian Rhythm; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - pathology; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fasting - blood; Female; Humans; Hypoglycemia - chemically induced; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Insulin - administration & dosage; Insulin - adverse effects; Insulin - agonists; Insulin - analogs & derivatives; Insulin - therapeutic use; Insulin Aspart; Insulin Detemir; Insulin, Long-Acting; Male; Type 2 diabetes; Variation in FPG; Weight
• ISSN: 0168-8227; 1872-8227
• DOI: 10.1016/j.diabres.2004.03.003

This trial compared the efficacy and safety of basal-bolus therapy using either the soluble basal insulin analogue insulin detemir (IDet) in combination with meal-time rapid-acting analogue insulin aspart (IAsp), or NPH insulin (NPH) in combination with meal-time regular human insulin (HSI). This was a 22-week, multinational, open-labelled, symmetrically randomised, parallel group trial including 395 people with type 2 diabetes (IDet + IAsp: 195, NPH + HSI: 200). At 22 weeks, HbA 1c was comparable between treatments (IDet + IAsp: 7.46%, NPH + HSI: 7.52%, P=0.515) with decreases from baseline of 0.65% and 0.58%, respectively. Treatment with IDet + IAsp was associated with a significantly lower within-person variation in self-measured fasting plasma glucose (FPG) (SD:1.20 versus 1.54 mmol/L, p